The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Allogeneic transplantation for myelofibrosis: Benefit of dose intensity.
Uday R. Popat
Research Funding - Otsuka
Roland Bassett
No relevant relationships to disclose
Julianne Chen
No relevant relationships to disclose
Amin Majid Alousi
No relevant relationships to disclose
Paolo Anderlini
No relevant relationships to disclose
Stefan O. Ciurea
No relevant relationships to disclose
Chitra Hosing
No relevant relationships to disclose
Roy B. Jones
No relevant relationships to disclose
Partow Kebriaei
No relevant relationships to disclose
Issa F. Khouri
No relevant relationships to disclose
Sergej Konoplev
No relevant relationships to disclose
Marcos De Lima
No relevant relationships to disclose
Yago Nieto
No relevant relationships to disclose
Betul Oran
No relevant relationships to disclose
Muzaffar H. Qazilbash
No relevant relationships to disclose
Gabriela Rondon
No relevant relationships to disclose
Elizabeth J. Shpall
No relevant relationships to disclose
Srdan Verstovsek
No relevant relationships to disclose
Borje Andersson
No relevant relationships to disclose
Richard E. Champlin
Research Funding - Otsuka